✦ LIBER ✦

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

✍ Scribed by Cameron, David; Brown, Julia; Dent, Rebecca; Jackisch, Christian; Mackey, John; Pivot, Xavier; Steger, Guenther G; Suter, Thomas M; Toi, Masakazu; Parmar, Mahesh; Laeufle, Rita; Im, Young-Hyuck; Romieu, Gilles; Harvey, Vernon; Lipatov, Oleg; Pienkowski, Tadeusz; Cottu, Paul; Chan, Arlene; Im, Seock-Ah; Hall, Peter S; Bubuteishvili-Pacaud, Lida; Henschel, Volkmar; Deurloo, Regula J; Pallaud, Celine; Bell, Richard

Book ID: 121009664
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 544 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70335-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line bevacizumab-containing thera

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

✍ Adam Brufsky, Vicente Valero, Beatrice Tiangco, Shaker Dakhil, Arija Brize, Hope 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 402 KB

5150 CIBOMA/2004–01: a randomised phase

5150 CIBOMA/2004–01: a randomised phase III trial assessing adjuvant capecitabine (X) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC)

✍ Lluch, A.; Torrecillas, L.; Barrios, C.H.; Bines, J.; Gómez, H.; Getulio, J.; Ru 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Biomarker results from the AVADO phase 3

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

✍ Miles, D W; de Haas, S L; Dirix, L Y; Romieu, G; Chan, A; Pivot, X; Tomczak, P; 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 366 KB

Bevacizumab plus paclitaxel versus bevac

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

✍ Lang, Istvan; Brodowicz, Thomas; Ryvo, Larisa; Kahan, Zsuzsanna; Greil, Richard; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 420 KB

1423 POSTER Polymorphism Analysis in the

1423 POSTER Polymorphism Analysis in the AVADO Randomised Phase III Trial of First-line Bevacizumab (BEV) Combined With Docetaxel in HER2-negative Metastatic Breast Cancer (mBC)

✍ D.W. Miles; S.L. De Haas; G. Romieu; A. Chan; L. Dirix; J. Cortes; P.R. Delmar; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Adjuvant chemotherapy and timing of tamo

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

✍ Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burto 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 145 KB